Andrew Ambrosy

San Francisco, USA

Andrew P. Ambrosy, MD is a general cardiologist at Kaiser Permanente San Francisco Medical Center and a clinician-investigator with the Kaiser Permanente Northern California Division of Research. He serves as Associate Program Director for Research in the Cardiovascular Disease Fellowship and as Local Research Chair at Kaiser Permanente San Francisco Medical Center, the region’s tertiary referral center for cardiovascular care. Dr. Ambrosy’s research program focuses on advancing cardiovascular, kidney, and metabolic health through innovative clinical trials, real-world data, and pragmatic research embedded in a learning health system. He completed a research fellowship at the Duke Clinical Research Institute, where he contributed to large NIH- and industry-sponsored trials, including PIONEER-HF and HEART-FID, and played a key role in the clinical development of Entresto™, now a first-line therapy for heart failure with reduced ejection fraction. He currently serves as National Lead Investigator for MOONRAKER, the largest global heart failure program evaluating finerenone, and ICONIC-HF, assessing intravenous ferric derisomaltose in heart failure. He also serves on the Steering Committee for DETECT-HF, a digital health trial evaluating the Cordio HearO™ app, chairs the Clinical Events Committee for RECOVER-HF, and led the phase I PK/PD study of bumetanide nasal spray to support regulatory approval. Dr. Ambrosy's research is supported by the National Institutes of Health (NIH), American Heart Association (AHA), Food and Drug Administration (FDA), The Permanente Medical Group, and industry sponsors. He has authored over 275 peer-reviewed manuscripts, presented at major national and international conferences, and serves as Editor-in-Chief of Heart Failure Reviews, Associate Editor for the American Heart Journal, Associate Editor for ESC Heart Failure, and on the editorial board of the Journal of Cardiac Failure.